Valencia Oncology Institute Foundation / Fundación Instituto Valenciano de Oncología / Fundació Institut Valencià d’Oncologia (IVO)

Hospital

Location: Valencia, Spain (ES)

ISNI: 000000041771144X

ROR: https://ror.org/01fh9k283

Show on Map:

Publications

(25)

Patient selection for accelerated partial breast irradiation (APBI) after breast-conserving surgery: Updated evidence-based recommendations of the Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) Breast Cancer Working Group (2026) Polgár C, Gutierrez-Miguelez C, Ivanov O, Smanykó V, Stankiewicz M, Martínez I, Lössl K, et al. Journal article, Review article Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial (2024) Harbeck N, Ciruelos E, Jerusalem G, Müller V, Niikura N, Viale G, Bartsch R, et al. Journal article Publisher Correction: Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial(Nature Medicine, 10.1038/s41591-024-03261-7) (2024) Harbeck N, Ciruelos E, Jerusalem G, Müller V, Niikura N, Viale G, Bartsch R, et al. Journal article, Erratum GEC-ESTRO recommendations for head & neck cancer brachytherapy (interventional radiotherapy): 2nd update with focus on HDR and PDR (2024) Guinot JL, Bacorro W, Budrukkar A, Bussu F, Gonzalez-Perez V, Jaberi R, Martinez-Monge R, et al. Journal article Very accelerated partial breast irradiation in 1 or 2 days: Late toxicity and early oncological outcome of the GEC-ESTRO VAPBI cohort (2024) Hannoun-Levi JM, Gimeno Morales M, Gal J, Anchuelo J, Guinot JL, Gastanaga M, Meszaros N, et al. Journal article Accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy compared with whole-breast irradiation with boost for early breast cancer: 10-year results of a GEC-ESTRO randomised, phase 3, non-inferiority trial (2023) Strnad V, Polgár C, Ott O, Hildebrandt G, Kauer-Dorner D, Knauerhase H, Major T, et al. Journal article The value of GLI1 and p16 immunohistochemistry in the premolecular screening for GLI1-altered mesenchymal neoplasms (2023) Machado I, Agaimy A, Giner F, Navarro S, Michal M, Bridge J, Claramunt R, et al. Journal article Prognostic impact of variant histologies in urothelial bladder cancer treated with radical cystectomy (2023) Claps F, van de Kamp MW, Mayr R, Bostrom PJ, Shariat SF, Hippe K, Bertz S, et al. Journal article In Regard to Rahimi et al. (2022) Hannoun-Levi JM, Guinot JL, Gutierrez C, Polgar C, Strnad V Journal article Response to Escande et al.: Magnetic guided brachytherapy: Time for non-pelvic cancer? Example from tongue brachytherapy [1] (2021) Kovács G, Martinez-Monge R, Budrukkar A, Guinot JL, Johansson B, Strnad V, Rovirosa A, et al. Journal article

‹ 1 2 3 ›